Cite
HARVARD Citation
Bang, Y. et al. (n.d.). 661PUpdated results from a phase I trial of M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-β, in patients with pretreated recurrent or refractory gastric cancer. Annals of oncology. p. . [Online].